Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSG005 in Invasive Fungal Infection
NCT06678113Phase 2Recruiting
- Sponsor
- Biosergen
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BSG005 in invasive fungal infection (IFI), sponsored by Biosergen. Primary endpoint: Safety and Tolerability of BSG005. Started Jul 2024; status: recruiting.
02
Drugs
BSG005
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT06678113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678113.